Publications by authors named "Ayman M Zaki"
The aim of this study was to assess the efficacy and safety of two protocols for retreatment of a cohort of Egyptian patients with chronic hepatitis C (CHC) who relapsed after NS5A inhibitor-based therapy. We conducted a prospective cohort study to assess the safety and efficacy of 12 weeks' retreatment with either combination of sofosbuvir/daclatasvir/simeprevir plus ribavirin (SOF/DCV/SMV/RBV, n = 45) or sofosbuvir/ombitasvir/paritaprevir/ritonavir plus ribavirin (SOF/OBV/PTV/r/RBV, n = 163) in patients who had previously failed NS5A inhibitors-based regimens. The primary end point was SVR 12 weeks after the end of treatment (SVR12).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the phenomenon of occult hepatitis C infection (OCI) in Egyptian patients who achieved sustained virologic response (SVR) after treatment with direct-acting antiviral agents (DAAs).
- A total of 150 patients with chronic hepatitis C were tested for HCV RNA in their blood cells, revealing that 11.33% of them had positive results despite showing no active infection in serum.
- The research suggests that dual testing for HCV RNA in both serum and blood cells is essential to accurately assess the presence of OCI post-treatment, particularly after DAA therapy.